Rexahn Pharmaceuticals, Inc. to Present Data on the Mechanism of Action of RX-5902: a First-in-Class Inhibitor of p68 Helicase for the Treatment of Solid Tumors at American Association for Cancer Research Annual Meeting 2013

Published: Apr 02, 2013

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that it will present mechanism of action data on RX-5902 during a poster session at the American Association for Cancer Research (AACR) 104th Annual Meeting being held in Washington, DC, April 6-10, 2013, at the Washington Convention Center.

Back to news